w 7 has been researched along with Malignant Melanoma in 6 studies
W 7: RN given refers to parent cpd; structure; calmodulin antagonist
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tamoxifen (TAM) markedly increases the response rate of malignant melanoma to treatment with cisplatin (DDP), carmustine, and dacarbazine, and we have previously reported that there is a highly synergistic interaction between TAM and DDP with respect to the cytotoxic effect against the human melanoma cell line T-289 (E." | 7.68 | Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. ( Albright, KD; Christen, RD; Howell, SB; Jones, JA; McClay, EF, 1993) |
| "Tamoxifen (TAM) markedly increases the response rate of malignant melanoma to treatment with cisplatin (DDP), carmustine, and dacarbazine, and we have previously reported that there is a highly synergistic interaction between TAM and DDP with respect to the cytotoxic effect against the human melanoma cell line T-289 (E." | 3.68 | Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. ( Albright, KD; Christen, RD; Howell, SB; Jones, JA; McClay, EF, 1993) |
| "Two drugs known to inhibit the action of calmodulin, prochlorperazine offP) and N-(6-aminohexyl)-5-chloro-1-napthalene sulfonamide (W7), were investigated for their ability to control cell proliferation in murine B16 melanoma cells in culture." | 3.67 | Effects of extracellular calmodulin and calmodulin antagonists on B16 melanoma cell growth. ( Bleehen, SS; Mac Neil, S; Senior, HJ; Tomlinson, S; Walker, SW, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Walker, SW | 2 |
| Mac Neil, S | 2 |
| Senior, HJ | 2 |
| Bleehen, SS | 2 |
| Tomlinson, S | 2 |
| Ito, H | 1 |
| Hidaka, H | 1 |
| McClay, EF | 1 |
| Albright, KD | 1 |
| Jones, JA | 1 |
| Christen, RD | 1 |
| Howell, SB | 1 |
| Kitagawa, T | 1 |
| Amano, F | 1 |
| Akamatsu, Y | 1 |
| Lönn, U | 1 |
| Lönn, S | 1 |
6 other studies available for w 7 and Malignant Melanoma
| Article | Year |
|---|---|
Calmodulin activation of cyclic AMP phosphodiesterase in the B16 mouse melanoma.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Calmodulin; Cells, Cultured; Cyclic AMP; Enzyme Activa | 1984 |
Antitumor effect of calmodulin antagonist against MH-134 hepatoma, Ehrlich ascites carcinoma and B-16 melanocarcinoma in mice.
Topics: Animals; Calmodulin; Carcinoma, Ehrlich Tumor; Liver Neoplasms, Experimental; Melanoma; Mice; Neopla | 1983 |
Effects of extracellular calmodulin and calmodulin antagonists on B16 melanoma cell growth.
Topics: Animals; Calmodulin; Cell Line; Cells, Cultured; Culture Media; DNA, Neoplasm; Dose-Response Relatio | 1984 |
Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.
Topics: Antineoplastic Agents; Calmodulin; Cell Cycle; Cisplatin; Drug Resistance; Drug Synergism; Enzyme In | 1993 |
External ATP-induced passive permeability change and cell lysis of cultured transformed cells: action in serum-containing growth media.
Topics: Adenosine Triphosphate; Animals; Blood; Calcium; Calmodulin; Cell Membrane Permeability; Cell Surviv | 1988 |
W-7, a calmodulin inhibitor, potentiates dacarbazine cytotoxicity in human neoplastic cells.
Topics: Calmodulin; Cell Division; Cell Line; Cell Survival; Dacarbazine; DNA Repair; DNA Replication; DNA, | 1987 |